Cancer Vaccines Market Set for 36% CAGR Through 2036 Fueled by Neoantigen and mRNA Therapies
TL;DR Summary
DelveInsight forecasts a 36% CAGR for the cancer vaccines market in the 7 major markets from 2026–2036, rising from about USD 335 million in 2025 as incidence grows and a robust pipeline (OSE-2101, Intismeran Autogene, IO102-IO103, CAN-2409, GPS, BNT113, and others) advances. The US leads with roughly 87% of 7MM sales in 2025, with melanoma, NSCLC, prostate, breast, and other solid tumors driving growth and an increasing focus on neoantigen/mRNA vaccines and combination strategies.
- Cancer Vaccines Market Anticipates Impressive Growth Trajectory at a CAGR of 36% During the Forecast Period (2026-2036) | DelveInsight PR Newswire
- A melanoma vaccine was hailed as a breakthrough. Which cancers are next? The Washington Post
- New treatment offers hope for melanoma Fox 59
- Don’t Let COVID Misinformation Block Access to Cancer Breakthroughs RealClearHealth
- Cancer vaccine sales to surge as immunotherapy moves mainstream Healthcare Asia Magazine
Reading Insights
Total Reads
0
Unique Readers
7
Time Saved
17 min
vs 17 min read
Condensed
98%
3,389 → 74 words
Want the full story? Read the original article
Read on PR Newswire